 |
This VA-HIT study took people with normal LDL-cholesterol and
either lower HDL or elevated triglyceride and randomized them after myocardial infarction
to gemfibrozil or placebo. Both in the diabetic and nondiabetic patients it was 24%
reduction in recurrent events almost achieving significance in the diabetic subgroup. This
study provide strong suggestion that fibrates may be of benefit in secondary prevention
and even at primary prevention among diabetic patients with the typical diabetic
dyslipidaemia. |
